Immunotherapy with anti-PD1/PD-L1 antibodies has become a major breakthrough in the treatment of NSCLC.[9–11] However, drug resistance in primary and secondary lung cancer eventually leads to the failure of targeted therapy in all patients.[12,13] Traditional has been shown to have a certain effect on lung cancer. This evidence concerns the gene CD274 and lung cancer.